Clinical Trials

NCT Number: NCT04729114 Phase: Phase 1|Phase 2 Trial Summary: A Phase 1/2a, open-label, multicenter study of intramuscular (i.m.) PRL-02 depot in participants with advanced prostate cance – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Astellas Pharma Global Development, Inc. Acronym:

NCT Number: NCT04471727 Phase: Phase 1|Phase 2 Trial Summary: A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 Monotherapy and HPN328 With Atezolizumab i – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, […]

NCT Number: NCT06202820 Phase: NA Trial Summary: This research is being done to test a program to assess and manage reversible cardiovascular (CV) risk factors in participants with prostate cancer starting androgen deprivation therapy (ADT), with th – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Dana-Farber Cancer Institute Acronym:

NCT Number: NCT06461416 Phase: NA Trial Summary: Aim 1: To determine the preliminary effect sizes of al ActiveHeal EST (Engage-Sustain-Triumph) Program on occupational resilience. – clinicaltrials.gov for more information and locations * Aim 2: To determine the preliminary effect sizes of ActiveHeal ES – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of […]

NCT Number: NCT06369246 Phase: PHASE2 Trial Summary: To look at the safety and effectiveness of stereotactic body radiation therapy (SBRT) in treating advanced or high-risk prostate cancer. – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): M.D. Anderson Cancer Center Acronym:

NCT Number: NCT06062745 Phase: PHASE1 Trial Summary: This research study is studying a positron emission tomography (PET) agent called 18F-fluciclovine to evaluate how well 18F-fluciclovine-PET scans determine the extent of advanced prostate cancer that – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Brigham and Women’s Hospital Acronym:

NCT Number: NCT06239194 Phase: PHASE1|PHASE2 Trial Summary: This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors. – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): ModeX Therapeutics, An OPKO Health Company Acronym:

NCT Number: NCT05919329 Phase: PHASE4 Trial Summary: This clinical trial investigates the change in prostate-specific membrane antigen (PSMA) expression in response to hormonal therapy in both, Castration Sensitive Prostate Cancer (CSPC) and Castration – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): OHSU Knight Cancer Institute Acronym:

NCT Number: NCT05113537 Phase: PHASE1|PHASE2 Trial Summary: This phase I/II trial tests the safety, side effects, and best dose of abemaciclib and whether it works before 177Lu-PSMA-617 in treating patients with castration resistant prostate cancer that has sp – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Vadim S Koshkin Acronym: UPLIFT

NCT Number: NCT06099093 Phase: PHASE4 Trial Summary: The purpose of this research study is to see how well an imaging test, called 18FDCFPyL prostate specific membrane antigen (PSMA) positron emission tomography (PET), can show the extent of prostate ca – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Brigham and Women’s Hospital Acronym: